The US Food and Drug Administration (FDA) has granted accelerated approval to Vimkunya™, a recombinant chikungunya vaccine, ...

Chikungunya, caused by the chikungunya virus (CHIKV) and spread through mosquito bites, leads to fever, rash, fatigue, headache, and severe joint pain. While rarely fatal, it can lead to long ...

If authorised, Vimkunya would be the first vaccine in the EU to protect individuals aged 12 and older against chikungunya, a mosquito-borne disease that leads to fever and joint pain. While most ...

As a bonus, Bavarian Nordic also gets a priority review voucher from the FDA, awarded as an incentive to carry out drug ...

Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8 mL dose.

The US Food and Drug Administration (FDA) has approved Bavarian Nordic’s chikungunya vaccine Vimkunya for use in individuals ...

Chikungunya is an emerging global health threat ... It causes fever and debilitating joint pain – as well as muscle aches, joint swelling, headache, nausea, fatigue, and rash – and in severe ...

Sri Lanka is experiencing a rise in Chikungunya cases, with the highest number of infections being reported across the country. ..

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger ...

The Davao City Health Office is monitoring five suspected cases of chikungunya, with an increase in cases reported in ...